Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Phase 2

Terminated

Conditions: Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2006-08-15

Last Posted Date: 2015-02-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00363883

Locations: 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: vorinostat
Drug: cytarabine
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00357305

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Philadelphia Chromosome Negative Chronic Myelogenous Leukemia
Previously Treated Myelodysplastic Syndromes

Interventions: Drug: decitabine
Drug: vorinostat
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-07-27

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00357708

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Suberoylanilide hydroxamic acid

First Posted Date: 2006-06-13

Last Posted Date: 2014-05-21

Lead Sponsor: University of Southern California

Target Recruit Count: 10

Registration Number: NCT00336141

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Nasopharyngeal Undifferentiated Carcinoma
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7

Interventions: Drug: Azacitidine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vorinostat

First Posted Date: 2006-06-12

Last Posted Date: 2024-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00336063

Locations: 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Previously Treated Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Promyelocytic Leukemia (M3)
Blastic Phase Chronic Myelogenous Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Interventions: Drug: vorinostat
Drug: idarubicin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-05-31

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00331513

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: doxorubicin hydrochloride
Drug: vorinostat
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-05-31

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00331955

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2006-05-26

Last Posted Date: 2014-05-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00330161

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: vorinostat
Drug: isotretinoin

First Posted Date: 2006-05-11

Last Posted Date: 2021-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00324740

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: vorinostat
Other: pharmacological study

First Posted Date: 2006-05-11

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00324480

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy